Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company, has announced its Q2 2024 financial results and business updates will be released on August 8, 2024, before market open. The company will host a live earnings call at 8:30 am ET / 6:30 am MT on the same day. This event will be streamed live on Recursion's social media platforms including X (formerly Twitter), LinkedIn, and YouTube.
The call is free and open to the public, with a focus on engaging a broad audience and providing opportunities for questions. Interested parties can submit questions in advance through a provided link. This approach demonstrates Recursion's commitment to transparency and shareholder engagement.
Recursion (NASDAQ: RXRX), una delle principali aziende TechBio in fase clinica, ha annunciato che i risultati finanziari del secondo trimestre del 2024 e gli aggiornamenti aziendali saranno rilasciati il 8 agosto 2024, prima dell'apertura del mercato. L'azienda ospiterà una call sui risultati in diretta alle 8:30 ET / 6:30 MT lo stesso giorno. Questo evento sarà trasmesso in diretta sulle piattaforme social di Recursion, inclusi X (precedentemente Twitter), LinkedIn e YouTube.
La call è gratuita e aperta al pubblico, con un focus sull'engagement di un vasto pubblico e opportunità per domande. Le parti interessate possono inviare domande in anticipo tramite un link fornito. Questo approccio dimostra l'impegno di Recursion per la trasparenza e il coinvolgimento degli azionisti.
Recursion (NASDAQ: RXRX), una empresa líder en la etapa clínica de TechBio, ha anunciado que los resultados financieros del segundo trimestre de 2024 y las actualizaciones comerciales se publicarán el 8 de agosto de 2024, antes de la apertura del mercado. La compañía realizará una conferencia de resultados en vivo a las 8:30 am ET / 6:30 am MT el mismo día. Este evento será transmitido en vivo a través de las plataformas sociales de Recursion, incluyendo X (anteriormente Twitter), LinkedIn y YouTube.
La llamada es gratuita y abierta al público, con un enfoque en atraer a una amplia audiencia y ofrecer oportunidades para preguntas. Las partes interesadas pueden enviar preguntas con anticipación a través de un enlace proporcionado. Este enfoque demuestra el compromiso de Recursion con la transparencia y la participación de los accionistas.
Recursion (NASDAQ: RXRX), 임상 단계의 선도적인 TechBio 회사,는 2024년 2분기 재무 결과와 사업 업데이트가 2024년 8월 8일 시장 개장 전에 발표될 것이라고 알렸습니다. 회사는 같은 날 오전 8시 30분 ET / 오전 6시 30분 MT에 실시간 실적 발표 전화 회의를 개최할 예정입니다. 이 이벤트는 Recursion의 소셜 미디어 플랫폼을 통해 생중계됩니다. 여기에는 X(구 Twitter), LinkedIn 및 YouTube가 포함됩니다.
이 전화 회의는 무료이며 대중에게 개방되어 있습니다. 넓은 청중을 유도하고 질문할 기회를 제공하는 데 중점을 두고 있습니다. 관심 있는 분들은 제공된 링크를 통해 미리 질문을 제출할 수 있습니다. 이러한 접근 방식은 Recursion이 투명성과 주주 참여에 대한 헌신을 보여줍니다.
Recursion (NASDAQ: RXRX), une entreprise TechBio de premier plan en phase clinique, a annoncé que ses résultats financiers du deuxième trimestre 2024 et ses mises à jour commerciales seront publiés le 8 août 2024, avant l'ouverture des marchés. La société organisera un appel de résultats en direct à 8h30 ET / 6h30 MT le même jour. Cet événement sera diffusé en direct sur les plateformes de médias sociaux de Recursion, y compris X (anciennement Twitter), LinkedIn et YouTube.
L'appel est gratuit et ouvert au public, avec un accent sur l'engagement d'un large public et la fourniture d'opportunités pour des questions. Les parties intéressées peuvent soumettre des questions à l'avance via un lien fourni. Cette approche démontre l'engagement de Recursion envers la transparence et l'engagement des actionnaires.
Recursion (NASDAQ: RXRX), ein führendes Unternehmen im klinischen TechBio-Bereich, hat bekannt gegeben, dass die Finanzzahlen für das zweite Quartal 2024 und Unternehmensaktualisierungen am 8. August 2024 vor Markteröffnung veröffentlicht werden. Das Unternehmen wird am selben Tag um 8:30 Uhr ET / 6:30 Uhr MT eine Live-Übertragung der Ergebnisbesprechung veranstalten. Diese Veranstaltung wird live auf den Social-Media-Plattformen von Recursion übertragen, einschließlich X (ehemals Twitter), LinkedIn und YouTube.
Der Anruf ist kostenlos und öffentlich zugänglich, mit dem Ziel, ein breites Publikum zu erreichen und Fragen zu ermöglichen. Interessierte Parteien können im Voraus über einen bereitgestellten Link Fragen einreichen. Dieser Ansatz zeigt das Engagement von Recursion für Transparenz und das Engagement der Aktionäre.
- Recursion is providing transparent and accessible financial reporting
- The company is engaging with a broad audience through multiple social media platforms
- Public participation and question submission are encouraged, indicating openness to investor inquiries
- None.
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets.
Recursion will host a L(earnings) Call on August 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open to the public and encouraged, especially for those wishing to ask questions. Questions can be submitted at https://forms.gle/1LNMHJyWwUuH9sqJ8.
About Recursion
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.
Media Contact
Media@Recursion.com
Investor Contact
Investor@Recursion.com
FAQ
When will Recursion (RXRX) report its Q2 2024 financial results?
What time is Recursion's (RXRX) Q2 2024 earnings call scheduled for?
How can investors participate in Recursion's (RXRX) Q2 2024 earnings call?
Can investors ask questions during Recursion's (RXRX) Q2 2024 earnings call?
